These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17951100)

  • 41. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular advances of brain tumors in radiation oncology.
    Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
    Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apoptosis: target of cancer therapy.
    Ferreira CG; Epping M; Kruyt FA; Giaccone G
    Clin Cancer Res; 2002 Jul; 8(7):2024-34. PubMed ID: 12114400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Awaiting a new era of cancer immunotherapy.
    Hong CW; Zeng Q
    Cancer Res; 2012 Aug; 72(15):3715-9. PubMed ID: 22815525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer.
    Harrington K; Jankowska P; Hingorani M
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):561-71. PubMed ID: 17591437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical applications of newer radionuclide therapies.
    Brans B; Linden O; Giammarile F; Tennvall J; Punt C
    Eur J Cancer; 2006 May; 42(8):994-1003. PubMed ID: 16564689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. At a crossroads in oncology.
    Kamb A
    Curr Opin Pharmacol; 2010 Aug; 10(4):356-61. PubMed ID: 20542731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defining a future role for radiogenic therapy.
    Kaminski JM; Kaminski RJ; Dicker AP; Urbain JL
    Cancer Treat Rev; 2001 Oct; 27(5):289-94. PubMed ID: 11871865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Direct molecular analysis of single disseminated cancer cells: a prerequisite for the development of adjuvant therapies?].
    Klein CA
    Acta Med Austriaca Suppl; 2002; 59():10-3. PubMed ID: 12506754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination approaches to immunotherapy: the radiotherapy example.
    Gough MJ; Crittenden MR
    Immunotherapy; 2009 Nov; 1(6):1025-37. PubMed ID: 20635917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The elusive goal: presidential address.
    Clarkson BD
    Cancer Res; 1981 Dec; 41(12 Pt 1):4865-84. PubMed ID: 7030481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer growth and progression in the framework of comparative oncology. A new approach to cancer therapy.
    Kaiser HE
    Anticancer Res; 1991; 11(4):1453-67. PubMed ID: 1746903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunologically augmented cancer treatment using modern radiotherapy.
    Durante M; Reppingen N; Held KD
    Trends Mol Med; 2013 Sep; 19(9):565-82. PubMed ID: 23831337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Towards a holistic vision of cancer].
    Solary É; Laplane L
    Med Sci (Paris); 2016 Apr; 32(4):315-6. PubMed ID: 27137681
    [No Abstract]   [Full Text] [Related]  

  • 56. [The medical oncology clinic].
    Velu T; Brandenburger A; Bruyns C; Gangji D; Tenenbaum L
    Rev Med Brux; 2002; 23 Suppl 2():131-6. PubMed ID: 12584929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy.
    Gough MJ; Crittenden MR; Young KH
    Immunotherapy; 2015; 7(8):847-9. PubMed ID: 26268988
    [No Abstract]   [Full Text] [Related]  

  • 58. Combining bioreductive drugs and radiation for the treatment of solid tumors.
    Stratford IJ; Williams KJ; Cowen RL; Jaffar M
    Semin Radiat Oncol; 2003 Jan; 13(1):42-52. PubMed ID: 12520463
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities.
    Green M; Feng FY; Mehra R; Spratt DE
    Immunotherapy; 2017 Aug; 9(9):695-699. PubMed ID: 28771102
    [No Abstract]   [Full Text] [Related]  

  • 60. Hallmarks of cancer: of all cancer cells, all the time?
    Floor SL; Dumont JE; Maenhaut C; Raspe E
    Trends Mol Med; 2012 Sep; 18(9):509-15. PubMed ID: 22795735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.